TuisASRT • NASDAQ
add
Assertio Holdings Inc
Vorige sluiting
$0,59
Dagwisseling
$0,57 - $0,61
Jaarwisseling
$0,51 - $1,80
Markkapitalisasie
56,80 m USD
Gemiddelde volume
449,56 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 32,18 m | -2,43% |
Bedryfskoste | 29,37 m | 0,05% |
Netto inkomste | -10,48 m | 81,74% |
Netto winsgrens | -32,55 | 81,29% |
Wins per aandeel | -0,03 | -127,27% |
EBITDA | -2,09 m | -76,37% |
Effektiewe belastingkoers | 2,54% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 100,05 m | 36,24% |
Totale bates | 284,73 m | -0,59% |
Totale aanspreeklikheid | 163,65 m | 10,27% |
Totale ekwiteit | 121,08 m | — |
Uitstaande aandele | 95,77 m | — |
Prys om te bespreek | 0,47 | — |
Opbrengs op bates | -7,85% | — |
Opbrengs op kapitaal | -13,24% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -10,48 m | 81,74% |
Kontant van bedrywe | 11,55 m | 102,35% |
Kontant van beleggings | 1,12 m | 567,78% |
Kontant van finansiering | -59,00 k | 99,34% |
Netto kontantverandering | 12,61 m | 465,74% |
Beskikbare kontantvloei | 16,78 m | 332,57% |
Meer oor
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration. On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor. Wikipedia
Gestig
1995
Hoofkwartier
Webwerf
Werknemers
58
